FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

ProteoStasis secures $45M in first round

Despite a lack of office space or even a complete research team, newcomer ProteoStasis Therapeutics has secured a whopping $45 million in Series A financing. Investors include Boston-based HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures.

The funds will support research and development for therapies to treat genetic, degenerative and metabolic disorders associated with protein homeostasis deficiencies. The startup's researchers are hoping that breakthroughs in understanding the onset of abnormal protein production will lead to more effective treatments for ailments such as Parkinson's disease, cystic fibrosis, diabetes, Alzheimer's and Huntington's.

- see the ProteoStasis release

Related Articles:
In VC market, life sciences dominate
Top 20 VC deals of 2007


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about ProteoStasis Therapeutics   Biotech Venture Capital